Sunitinib represents an acceptable option in first line treatment for metastatic papillary renal cell carcinoma (mPRCC), a recent study published early online in the journal Annals of Oncology has shown.
Because there is currently no standard first line treatment for mPRCC, researchers designed a prospective phase II study to evaluate sunitinib in first line treatment of patients with mPRCC.
Researchers enrolled 15 patients with type 1 and 46 patients with type 2 mPRCC. Of those, 12 were in the favorable risk group, 33 were in the intermediate risk group, 9 were in the poor risk group, and 7 were undetermined.
Results showed that at a median follow-up time of 51.4 months, 13% (95% CI: 0.1 – 30.5) of those with type mPRCC achieved a partial response, 67% had stable disease with 33% of patients having stable disease at least 12 weeks.
For those with type 2, 11% (95% CI: 1.9 – 20.3) achieved a partial response, 54% had stable disease with 22% of patients having stable disease at least 12 weeks.
RELATED: Urine Test for Kidney Cancer Showing Promise
Median progression-free survival was 6.6 months (95% CI: 2.8 – 14.8) and 5.5 months (95% CI: 3.8 – 7.1) for type 1 and type 2, respectively. Median overall survival was 17.8 months (95% CI: 5.7 – 26.1) for type 1 and 12.4 months (95% CI: 8.2 – 14.3).
The findings suggest that sunitinib shows activity in both types of mPRCC, but lower activity than in clear cell metastatic renal cell carcinoma (mRCC).